Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Texas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Texas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Texas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Neva Diagnostics (NPI 1104569730)

Field	Value
Entity Type	Organization
Organization	Neva Diagnostics
Address	12200 Ford Rd Ste A102
City	Farmers Branch
State	TX
ZIP	75234
Taxonomy	Clinical Medical Laboratory
NPI Enumerated	April 20, 2022

Payer Source	Total Paid
Medicare	$10M
Medicaid	$0

Key Findings

NEVA DIAGNOSTICS operates as a high-complexity clinical molecular laboratory focused on genetic and genomic testing rather than routine clinical chemistry or anatomic pathology. Its top Medicare revenue driver is 81419, a broad genomic sequence analysis panel, and the remainder of the top CPT/HCPCS codes are dominated by single-gene sequencing and repeat-expansion tests (for example, 81325, 81336, 81298, 81286 and multiple ATXN/HTT codes), which together indicate a service line centered on inherited disease and oncology-related molecular diagnostics. The presence of 87798 (amplified nucleic acid probe testing) in the top list also shows the lab performs some infectious-agent nucleic acid testing techniques alongside hereditary testing.

Revenue concentration is notable: the provider reports $10M in total Medicare revenue and its top 3 Medicare codes by revenue account for 43.7% of that Medicare revenue. The single largest code, 81419, generates $2.6M and represents 29.4% of Medicare revenue, indicating the business is materially dependent on a single comprehensive genomic panel for a large share of its Medicare receipts. This concentration highlights both the laboratory’s specialty strength and a potential single-test dependency risk for Medicare revenue stability.

NEVA DIAGNOSTICS is effectively a Medicare-centric operation: the dataset shows $10M in Medicare revenue and no Medicaid billing on file. This absence of Medicaid activity makes the provider effectively single-payer in the public program landscape and suggests limited state-plan footprint or billing to Medicaid, which may affect payer diversification and negotiations with state payers. Analysts should treat contracting and population coverage assumptions accordingly given the lack of recorded Medicaid claims.

For competitive standing on its top test, 81419 the provider is a major national participant: it ranks #2 of 27 providers nationally and sits in the 96th percentile, which the source characterizes as “notably above typical national volume.” That rank implies NEVA DIAGNOSTICS is one of the largest national performers for that panel. By contrast, 81325 ranks #6 of 23 (77th percentile) and is described as a typical, unremarkable volume level, indicating the provider’s dominance is concentrated in a smaller set of high-revenue panels rather than uniformly across all genetics codes.

Some codes show mixed positions versus national peers: 87798 appears with 13.3K claims and $450.8K revenue and ranks #119 of 1319 (91th percentile) yet is labeled in the file as a “typical, unremarkable volume” for that code. Similarly, several single-gene tests (for example, 81336 and 81177) appear at high rank positions (81336 at #2 of 6; 81177 at #2 of 12) and are described as typical-to-notably above typical, signaling that NEVA DIAGNOSTICS holds above-average placement on certain specialized assays while remaining more routine on many others. These mixed statistical labels suggest the lab has selective national leadership on a few high-value panels and more conventional volumes on a broader menu.

The provider’s tenure is short relative to legacy national labs: NPI enumeration occurred on 2022-04-20 (~4 years ago). Achieving $10M in Medicare revenue within this ~4-year window indicates rapid scaling in Medicare-facing genetic testing services. For competitive and operational analysis, this recent entry combined with concentrated revenue suggests growth driven by a narrow set of high-revenue molecular assays rather than a long-standing broad-service presence.

Operational and contracting implications from payer mix and code mix are significant: the lab’s service portfolio—heavy on comprehensive genomic panels and many single-gene sequencing codes—positions it for value with physician specialty referrals (genetics, neurology, oncology) but with limited Medicaid participation there may be gaps in coverage for dual-eligible or lower-income populations. Payors and provider partners evaluating network inclusion or risk-sharing should note the lab’s Medicare concentration and its reliance on a few top codes (as described above) when modeling utilization, access, and potential negotiation leverage.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

49 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
81419	The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in…	1,070	$2,400	$2.6M
81325	The lab analyst performs the technical lab test to analyze the entire gene sequence for the peripheral myelin protein 22, or PMP22, gene.	1,070	$750	$803.8K
87798	The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified…	13,260	$30	$450.8K
81317	The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene.	520	$660	$342.1K
81307	The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene.	510	$660	$334.6K
81298	The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene.	530	$630	$330.2K
81249	The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene.	540	$590	$318.1K
81336	The lab analyst performs the technical lab test to analyze the entire gene sequence for the survival of motor neuron 1 (SMN1), telomeric.	1,070	$300	$316.5K
81238	The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene.	520	$590	$304K
81309	The lab analyst performs the technical lab test to analyze specific gene sequences of the phosphatidylinositol–4, 5–biphosphate 3–kinase, catalytic subunit alpha (PIK3CA) gene.	1,060	$270	$284.6K

Showing 1–10 of 49

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 49 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Texas Distribution

Neva Diagnostics — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Texas

Full comparison — all codes billed, vs. state median

49 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
81419	1	10	80	$2,400	$666.2K
81325	3	10	90	$750	$582.2K
81317	3	20	220	$660	$382.7K
81298	3	20	220	$630	$362.7K
81307	4	20	150	$660	$361.4K
81249	3	20	80	$590	$319.2K
81336	1	10	1,070	$300	$316.9K
81238	3	20	110	$590	$281.7K
81309	3	10	110	$270	$278.9K
81189	3	10	110	$270	$278.2K

Showing 1–10 of 49

Nearby Providers

Other providers in the same ZIP code as Neva Diagnostics, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ricardo Martinez	TX	Family Medicine Physician	$2.4M	$0
Apollo Path, LLC	TX	Clinical Medical Laboratory	$936.1K	$797.1K
Hsiling Yu	TX	Family Nurse Practitioner	$297.9K	$0
Confirm Laboratory LLC	TX	Clinical Medical Laboratory	$200.1K	$0
Kathleen Moore	TX	Physical Therapist	$73.1K	$0
Brian Morrow	TX	Nurse Practitioner	$46.4K	$0
Eli Neiman	TX	Neurology Physician	$27.9K	$0
Elizabeth Cameron	TX	Certified Registered Nurse Anesthetist	$24.9K	$0

Neva Diagnostics — Billing Profile & Reimbursement Data

Sign up for Neva Diagnostics — Billing Profile & Reimbursement Data policy alerts

Neva Diagnostics — Billing Profile & Reimbursement Data

Sign up for Neva Diagnostics — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References